Tyrosine Kinase Inhibitor

In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the study he presented at ASCO21 that showed progression-free survival rates were equal among patients with CML treated with acalabrutinib vs. ibrutinib.

Tyrosine kinase inhibitor-sensitive genomic aberrations, unresected tumors and not smoking were associated with increased treatment failure in non-small cell lung cancer, according to a presentation at the virtual ASCO annual meeting.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about research on deucravacitinib presented at AAD VMX 2021.

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, spoke with Healio about the results and clinical implications of the POETYK PSO-1 and POETYK PSO-2 trials.

Evobrutinib, a Bruton’s tyrosine kinase inhibitor that targets B cells and myeloid cells, significantly decreased blood neurofilament light levels as early as 12 weeks in patients with MS, with sustained reductions through 24 weeks.

In this video, Andrew A. Moshfeghi, MD, MBA, discusses results from a phase 1 study of an intravitreal hydrogel axitinib implant for wet AMD he recently presented at the virtual Angiogenesis, Exudation, and Degeneration meeting.

Approximately 29% of older patients with chronic myeloid leukemia did not initiate tyrosine kinase inhibitor therapy within 6 months of diagnosis, according to study results published in Journal of Clinical Oncology.

Gilteritinib and quizartinib were well-tolerated and linked to improved survival and treatment response compared with salvage chemotherapy for relapsed or refractory FLT3 internal tandem duplication-mutated acute myeloid leukemia.

Patients with relapsed or refractory acute myeloid leukemia who received prior tyrosine kinase inhibitor – midostaurin or sorafenib – achieved remission with gilteritinib, an FLT3 inhibitor, according to data presented at ASH Annual Meeting and Exposition.

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020.